Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
29.83
+0.57 (+1.95%)
Streaming Delayed Price
Updated: 3:59 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
3
4
5
Next >
FDA Approves Genentech’s Evrysdi (risdiplam) for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)
May 31, 2022
From
Genentech
Via
Business Wire
New Pivotal Data Demonstrate Clinical Benefit of Genentech’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma
May 26, 2022
From
Genentech
Via
Business Wire
Data at the 2022 ASCO Annual Meeting Highlight Genentech’s Continued Commitment to Innovation in Oncology and Personalized Healthcare
May 24, 2022
From
Genentech
Via
Business Wire
Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
May 11, 2022
From
Genentech
Via
Business Wire
New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
April 29, 2022
From
Genentech
Via
Business Wire
New Data for Genentech’s Ocrevus (ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis
April 04, 2022
From
Genentech
Via
Business Wire
U.S. FDA Grants Priority Review to Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
April 04, 2022
From
Genentech
Via
Business Wire
Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer
March 30, 2022
From
Genentech
Via
Business Wire
New Data for Genentech’s Evrysdi (risdiplam) Demonstrate Long-Term Efficacy and Safety in a Broad Population of People With Spinal Muscular Atrophy (SMA)
March 16, 2022
From
Genentech
Via
Business Wire
New Two-Year Data for Genentech’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision With Fewer Treatments for People With Two Leading Causes of Vision Loss
February 11, 2022
From
Genentech
Via
Business Wire
FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss
January 28, 2022
From
Genentech
Via
Business Wire
Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)
January 25, 2022
From
Genentech
Via
Business Wire
The Lancet Publishes Studies Showing Genentech’s Faricimab Improved and Maintained Vision in Two Leading Causes of Vision Loss, Extending Time Between Treatments up to Four Months
January 24, 2022
From
Genentech
Via
Business Wire
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
January 14, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 14, 2022 – USA News Group – Cancer cases are on the rise, according to a new study comparing the number of cancer...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Genentech’s Polivy Combination Reduced the Risk of Disease Worsening or Death by 27% in People With Previously Untreated Aggressive Form of Lymphoma
December 14, 2021
From
Genentech
Via
Business Wire
Interim Data From Phase III HAVEN 6 Study Demonstrate Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A
December 13, 2021
From
Genentech
Via
Business Wire
Genentech Presents Pivotal Data at ASH 2021 for Novel Cancer Immunotherapy Mosunetuzumab
December 11, 2021
From
Genentech
Via
Business Wire
New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech’s Novel Anti-TIGIT Tiragolumab Plus Tecentriq
December 10, 2021
From
Genentech
Via
Business Wire
Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood Disorders
November 23, 2021
From
Genentech
Via
Business Wire
FDA Approves Genentech’s Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD)
October 22, 2021
From
Genentech
Via
Business Wire
FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer
October 15, 2021
From
Genentech
Via
Business Wire
NetworkNewsAudio – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Harnessing Power of Real-World Data
October 14, 2021
Via
Investor Brand Network
New 4-Year Data Show Genentech’s Enspryng (satralizumab-mwge) Significantly Reduces Debilitating Relapses in People With Neuromyelitis Optica Spectrum Disorder
October 14, 2021
From
Genentech
Via
Business Wire
New Data up to 8-Years for Genentech’s Ocrevus (ocrelizumab) Show Early and Ongoing Treatment Significantly Reduced Risk of Requiring a Walking Aid in Relapsing Multiple Sclerosis and Disability Progression in Primary Progressive Multiple Sclerosis
October 13, 2021
From
Genentech
Via
Business Wire
Real-World Data, Point-of-Care Testing Reshaping Healthcare, Detecting Diseases Sooner
October 12, 2021
Via
Investor Brand Network
Genentech’s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer’s Disease
October 08, 2021
From
Genentech
Via
Business Wire
Ad hoc announcement pursuant to Art. 53 LR: Genentech’s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer’s Disease
October 08, 2021
From
Genentech
Via
Business Wire
Genentech to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryng (satralizumab-mwge) in Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2021
October 05, 2021
From
Genentech
Via
Business Wire
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space
September 20, 2021
Via
FinancialNewsMedia
New Phase III Data Support the Benefit of Genentech’s Tecentriq in Early-stage Lung Cancer
September 20, 2021
From
Genentech
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.